← Patent-cliff monitor Loss of exclusivity October 2040 latest FDA-listed patent expiry
Drug detail Brand name CABENUVA KIT Active ingredient CABOTEGRAVIR; RILPIVIRINE Strength 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) Dosage form SUSPENSION, EXTENDED RELEASE Route INTRAMUSCULAR Modality Small molecule FDA approval January 2021 Marketing status RX
Listed patents Patent Expires Type 12636286 October 2040 use U-3348 12636285 October 2040 use U-3348 12178815 July 2038 use U-3348 11389448 April 2032 product RE50189 November 2031 use U-3348 11224597 September 2031 product 12138264 September 2031 product 8410103 February 2031 substance, product 11389447 June 2027 use U-3405 10927129 April 2026 substance, product
Regulatory exclusivity Code Expires NCE January 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.